Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6946 to 6960 of 8213 results

  1. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

  2. Ligelizumab for previously treated chronic spontaneous urticaria in people 12 years and over [ID3999]

    Discontinued Reference number: GID-TA10891

  3. Baricitinib for treating active autoantibody-positive systemic lupus erythematosus [ID3997]

    Discontinued Reference number: GID-TA10892

  4. Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

    In development Reference number: GID-TA10900 Expected publication date: TBC

  5. Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]

    In development Reference number: GID-TA10905 Expected publication date: TBC

  6. Tanezumab for treating pain caused by bone metastases [ID3784]

    Discontinued Reference number: GID-TA10922

  7. Nivolumab for neoadjuvant and adjuvant treatment of localised renal cell carcinoma [ID4047]

    Discontinued Reference number: GID-TA10927

  8. Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]

    Discontinued Reference number: GID-TA10934

  9. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development Reference number: GID-TA10935 Expected publication date: TBC

  10. Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID5081]

    Discontinued Reference number: GID-TA10963

  11. Bempegaldesleukin with nivolumab for untreated unresectable or metastatic melanoma

    Discontinued Reference number: GID-TA10970

  12. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]

    In development Reference number: GID-TA11010 Expected publication date: TBC

  13. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development Reference number: GID-TA11022 Expected publication date: TBC

  14. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development Reference number: GID-TA11070 Expected publication date: TBC

  15. Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]

    Discontinued Reference number: GID-TA10633